Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab.

Trial Profile

Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2012 Planned end date changed from 1 Aug 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 11 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top